By proceeding, you agree to our Terms of Use and Privacy Policy.
Cognivue is a risk assessment test that identifies changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It is the world's first FDA-Cleared computerized test of cognitive function. Cognivue was designed to objectively, quantitatively and reliably identify changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It allows clinicians the opportunity to establish a baseline cognitive score that can be monitored over time.
11-13 July 2023
The 2nd Digital Biomarkers & Clinical Measures in Neuro Summit is a groundbreaking event that is set to drive the digital revolution in the field of objective, sensitive, and non-invasive measures in Central Nervous System (CNS) research. With three
Event Ended
USA
Paid
Boston